Form 4: Chart Industries Director Equity Grant Disclosure

Sentiment:

Insider Transaction Report


Chart Industries Director Paul E. Mahoney received a grant of 193 shares of common stock under the company's 2024 Omnibus Equity Plan.

Summary

  • Paul E. Mahoney, a Director of Chart Industries, Inc. (GTLS), acquired 193 shares of common stock.
  • The transaction occurred on January 2, 2026.
  • These shares were granted at a price of $0, indicating an equity award rather than a purchase.
  • The grant was made pursuant to the Chart Industries, Inc. 2024 Omnibus Equity Plan.
  • The securities are deferred under the stock award agreement until a future date.
  • Following this transaction, Paul E. Mahoney beneficially owns 3,562 shares of Chart Industries common stock.

Sentiment

Score: 6

Explanation: Slightly positive as it represents a routine alignment of director and shareholder interests through equity compensation, without any negative implications.

Positives

  • The equity grant aligns the director's interests with those of shareholders, promoting long-term value creation.
  • The grant is part of a pre-existing, approved equity plan (2024 Omnibus Equity Plan), indicating a structured approach to executive and director compensation.

Negatives

  • No specific negatives are apparent from this routine insider transaction filing.

Risks

  • No specific risks are mentioned in this Form 4 filing.

Future Outlook

The granted securities are deferred until a future date, implying future vesting or delivery according to the terms of the stock award agreement.

Management Comments

  • "These securities were granted on January 2, 2026, in an exempt transaction, pursuant to the terms of a stock award agreement under the Chart Industries, Inc. 2024 Omnibus Equity Plan, and deferred under the stock award agreement until a future date."

Industry Context

Equity grants to directors are a standard practice across industries to incentivize long-term commitment and align leadership interests with shareholder value. This filing reflects a routine compensation component for a director.

Comparison to Industry Standards

  • Equity compensation for non-executive directors is a common practice in publicly traded companies, often comprising a significant portion of their total compensation.
  • The grant of 193 shares is a relatively small number, typical for a single director's annual equity award, especially when part of a broader compensation package.
  • Companies like General Electric (GE) or Honeywell (HON) also utilize similar omnibus equity plans to grant stock awards to their directors and executives, aligning their interests with company performance.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Equity Plan UtilizationThe grant was made under the Chart Industries, Inc. 2024 Omnibus Equity Plan, demonstrating the ongoing use of the company's approved equity compensation framework.01/02/2026Reinforces the company's established compensation policies and aligns director incentives with long-term company performance.

Stakeholder Impact

  • Shareholders: The equity grant aligns the director's financial interests with long-term shareholder value.
  • Employees: No direct impact on employees is indicated by this filing.

Next Steps

  • The deferred nature of the securities implies future vesting or delivery according to the terms of the stock award agreement.

Key Dates

DateDescription
01/02/2026Date of transaction (securities granted)
01/06/2026Date Form 4 was signed and filed

Keywords

Chart Industries, GTLS, Paul E. Mahoney, Director, Equity Grant, Insider Transaction, Form 4, Stock Award, Omnibus Equity Plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.